natgillin/translations-raw huggingface dataset:
optionally, carrying out one or more washes of the aqueous phase of step (a) with an organic solvent at a pH comprised between 8.5 and 10.0 and at a temperature comprised between 10 °C and about 5 °C below the boiling point of the mixture, and separating the aqueous phase containing the Montelukast in salt form; 
proizvoljno, provođenje jednog ili više ispiranja vodene faze iz koraka (a) sa organskim otapalom pri pH koji je između 8,5 i 10,0 i pri temperaturi koja je između 10 ° C i oko 5 °C ispod točke vrelišta mješavine, i odvajanja vodene faze koja sadrži Montelukast u obliku soli;
The purification process according to claim 7, wherein the Montelukast acid is isolated by filtration. 
Postupak pročišćavanja prema zahtjevu 7, naznačen time da je kiselina Montelukasta izolirana pomoću filtracije.
The purification process according to any of the claims 1-6, wherein the Montelukast is isolated from the organic phase of step (c) in salt form by adding a base and isolating from the reaction medium the corresponding pharmaceutically acceptable salt of Montelukast. 
Postupak pročišćavanja prema bilo kojem od zahtjeva 1-6, naznačen time da je Montelukast izoliran iz organske faze prema koraku (c) u obliku soli dodavanjem baze i izoliranjem iz reakcijskog medija odgovarajuće farmaceutski prihvatljive soli Montelukasta.
The purification process according to any of the claims 1-11, further comprising a previous step where a compound of formula (II) is reacted with an inorganic base in a mixture of an (C1-C6)-alcohol and water, to yield Montelukast crude. 
Postupak pročišćavanja prema bilo kojem od zahtjeva 1-11, naznačen time da nadalje sadrži prethodnim korak gdje spoj formule (II) [image] reagira s anorganskom bazom u mješavini (C1-C6)-alkohola i vode, da se dobije sirovi Montelukast.
adding an organic solvent and water and separating the aqueous phase; and 
dodavanje organskog otapala i vode i odvajanja vodene faze; te
carrying out an extraction of the Montelukast in salt form from the organic phase with water; to yield an aqueous phase containing Montelukast crude in salt form. 
provođenja ekstrakcije Montelukasta u obliku soli iz organske faze s vodom; da se dobije vodena faza koja sadrži sirovi oblik soli Montelukasta.
The purification process according to any of the claims 1-11, wherein the aqueous phase containing crude Montelukast in salt form is obtained by adding an aqueous solution of a base to a mixture of Montelukast acid and an organic solvent. 
Postupak pročišćavanja prema bilo kojem od zahtjeva 1-11, naznačen time da se vodena faza koja sadrži sirovi oblik soli Montelukasta dobiva dodavanjem vodene otopine baze u mješavinu kiseline Montelukasta i organskog otapala.
Use of a polymer fiber according to any of claims 1-4 or 7 as an additive, for example in concrete, mortar, plaster, cement or refractory material. 
Upotreba polimernog vlakna u skladu s patentnim zahtjevom 1, naznačena time što je navedeno polimerno vlakno aditiv za beton, žbuku, gips, cement ili vatrostalni materijal.
Concrete, mortar, plaster, cement or refractory material containing a polymer fiber according to any of claims 1-4 or 7. 
Beton, žbuka, gips, cement ili vatrostalni materijal, naznačeni time što sadrže polimerno vlakno u skladu s patentnim zahtjevom 1.
The cytotoxic conjugate according to claim 10, wherein said fragment of an antibody is selected from the group consisting of a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fd fragment, a single-chain Fvs (scFv) fragment, a single-chain antibody, a disulfide-linked Fvs (sdFv) fragment and a fragment comprising either a VL or VH domain. 
Citotoksični konjugat prema zahtjevu 10, naznačen time što se fragment protutijela odabire iz skupine koja obuhvaća Fab fragment, Fab’ fragment, F(ab’)2 fragment, Fd fragment, jednolančani Fvs (scFv) fragment, jednolančano protutijelo, disulfid-spojeni Fvs (sdFv) fragment i fragment koji sadrži ili VL ili VH domenu.
l m, n, o, p, q, r, s, and t are each independently 0 or an integer of from 1 to 5, provided that at least two of l, m, n, o, p, q, r, s and t are not zero at any one time; and Z is H, SR or -COR, wherein R is linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical. 
l, m, n, o, p, q, r, s i t su svaki nezavisno 0 ili cijeli broj od 1 do 5, uz uvjet da barem dva od l, m, n, o, p, q, r, s i t nisu nikad nula; i Z je H, SR ili -COR, pri čemu je R linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavni ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal.
The cytotoxic conjugate according to claim 15, wherein said cytotoxic agent is a maytansine selected from the group consisting of formulas (IV-L), (IV-D), and (IV-D,L): wherein: 
Citotoksični konjugat prema zahtjevu 15, naznačen time što je citotoksična tvar majtanzin izabran iz skupine koja obuhvaća formule (IV-L), (IV-D) i (IV-D,L): [image] gdje:
and R2 are each independently CH3, C2H5, linear alkyl or alkenyl having from 1 to 10 0 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, or heterocyclic aromatic or heterocycloalkyl radical, and in addition R2 can be H; 
i R2 su svaki nezavisno CH3, C2H5, linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, fenil, supstituirani fenil ili heterociklički aromatski ili heterocikloalkilni radikal, i dodatno R2 može biti H;
I, m and n are each independently an integer of from 1 to 5, and in addition n can be 0; Z is H. SR or -COR wherein R is linear or branched alkyl or alkenyl having from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, or simple or substituted aryl or heterocyclic aromatic or heterocycloalkyl radical; and May represents a maytansinoid which bears the side chain at C-3, C-14 hydroxymethyl, C-15 hydroxy or C-20 desmethyl. 
l, m i n su svaki nezavisno cijeli broj od 1 do 5, i dodatno n može biti 0; Z je H, SR ili -COR, pri čemu je R linearni ili razgranati alkil ili alkenil s 1 do 10 atoma ugljika, ciklički alkil ili alkenil s 3 do 10 atoma ugljika, ili jednostavni ili supstituirani aril ili heterociklički aromatski ili heterocikloalkilni radikal; i May predstavlja majtanzinoid koji nosi bočni lanac na C-3, C-14 hidroksimetil, C-15 hidroksi ili C-20 desmetil.
The cytotoxic conjugate according to claim 15. wherein said cytoloxic agent is a maytansine selected from the group consisting of formulas (VI-L), (VI-D), and (VI-D,L): wherein: 
Citotoksični konjugat prema zahtjevu 15, naznačen time što je citotoksična tvar majtanzin izabran iz skupine koja obuhvaća formule (VI-L), (VI-D) i (VI-D,L): [image] gdje:
and R2 are each independently CH3, C2H5, linear or branched alkyl or alkenyl having from 1 to 10 carbon atoms, cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl or heterocyclic aromatic or helerocycloalkyl radical, and in addition R2 can be H; 
i R2 su svaki nezavisno CH3, C2H5, linearni ili razgranati alkil ili alkenil s 1 do 10 atoma ugljika, ciklički alkil ili alkenil s 3 do 10 atoma ugljika, fenil, supstituirani fenil ili heterociklički aromatski ili heterocikloalkilni radikal, i dodatno R2 može biti H;
The cytotoxic conjugate according to claim 15, wherein said cytotoxic agent is a maytansine selected from the group consisting of formulas (IX-L), (IX-D), and (IX-D,L): wherein: 
Citotoksični konjugat prema zahtjevu 15, naznačen time što je citotoksična tvar majtanzin izabran iz skupine koja obuhvaća formule (IX-L), (IX-D) i (IX-D,L):
and R2 are each independently CH3, C2H5, linear alkyl or alkenyl having from 1 to 10 carbon atoms, branched or cyclic alkyl or alkenyl having from 3 to 10 carbon atoms, phenyl, substituted phenyl, heterocyclic aromatic or heterocycloalkyl radical, and in addition R2 can be H; 
i R2 su svaki nezavisno CH3, C2H5, linearni alkil ili alkenil s 1 do 10 atoma ugljika, razgranati ili ciklički alkil ili alkenil s 3 do 10 atoma ugljika, fenil, supstituirani fenil ili heterociklički aromatski ili heterocikloalkilni radikal, i dodatno R2 može biti H;
The method for inhibiting the growth of a cell expressing CA6 glycotope according to claim 52, wherein the cytotoxic conjugate comprises a humanized version of the murine antibody DS6 or an epitope-binding fragment thereof as the cell binding agent and DM1 or DM4 as the cytotoxic agent. 
Postupak inhibicije rasta stanica koje eksprimiraju CA6 glikotop, prema zahtjevu 52, naznačen time što citotoksični konjugat sadrži humaniziranu verziju mišjeg protutijela DS6 ili njegov fragment koji se veže za epitop kao tvar koja se veže za stanicu te DM1 ili DM4 kao citotoksičnu tvar.
The method for inhibiting the growth of a cell expressing CA6 glycotope according to claim 52, wherein the cytotoxic conjugate comprises a humanized version of the murine antibody DS6 or an epitope-binding fragment thereof as the cell binding agent and a taxane as the cytotoxic agent. 
Postupak inhibicije rasta stanica koje eksprimiraju CA6 glikotop, prema zahtjevu 52, naznačen time što citotoksični konjugat sadrži humaniziranu verziju mišjeg protutijela DS6 ili njegov fragment koji se veže za epitop kao tvar koja se veže za stanicu te taksan kao citotoksičnu tvar.
A therapeutic composition, comprising a cytotoxic conjugate according to claim 10 and a pharmaceutically acceptable carrier or excipient. 
Smjesa za liječenje, naznačena time što sadrži citotoksični konjugat prema zahtjevu 10 i farmaceutski prihvatljivi nosač ili pomoćnu tvar.
The use or composition of claims 60 and 61, wherein the cancer is one in which CA6 glycotope is expressed or overexpressed. 
Uporaba ili smjesa prema zahtjevima 60 i 61, naznačena time što je rak takav da se CA6 glikotop eksprimira ili prekomjerno eksprimira.
The use or composition of claims 60 and 61, wherein the cancer is selected from the group consisting of serous ovarian carcinoma, endometriod ovarian carcinoma, neoplasm of the uterine cervix, neoplasm of the endometrius, neoplasm of the vulva, breast carcinoma, pancreatic tumor, and tumor of the urothelium. 
Uporaba ili smjesa prema zahtjevima 60 i 61, naznačena time što se radi o raku izabranom iz skupine koja obuhvaća serozni karcinom jajnika, endometriodni karcinom jajnika, neoplazme cerviksa maternice, neoplazme endometrija, neoplazme vulve, rak dojke, tumor gušterače i tumor urotelijuma.
a compartment comprising the cytotoxic conjugate. 
odjeljak koji sadrži citotoksični konjugat.
PLASTIC NET BAG, as per claim 1, characterized by the fact that the laminar strip (5) is located on the exterior of the fold that encompasses the strip and the mesh, and the tubular mesh element (2) is located on the interior of this fold and is fully gathered within the width of the laminar strip (5), where these relative positions of the strip and the mesh can be altered. 
Plastična mrežasta vrećica, prema zahtjevu 1, naznačena time da se laminarna traka (5) nalazi s vanjske strane preklopa koji obuhvaća traku i mrežu, te se cjevasti mrežni element (2) nalazi u unutrašnjosti navedenog preklopa gdje je u potpunosti skupljen unutar širine laminarne trake (5), te gdje se relativne pozicije trake i mreže mogu mijenjati.
PLASTIC NET BAG, as per claims 1 and 2, characterized by the fact that the length (L1) of the lines or areas of welding (6 and 7) can be variable, preferentially encompassing the whole width of the laminar strip (5) and the closures of the bag (3 and 4), with these width values preferentially ranging from 30 mm. to 200 mm., and more specifically from 40 to 70 mm. 
Plastična mrežasta vrećica, prema zahtjevima 1 i 2, naznačena time da duljina (L1) linija ili područja zavarivanja (6 i 7) može varirati, te poželjno obuhvaća cijelu širinu laminarne trake (5) i elemenata za zatvaranje vrećice (3 i 4), s time da su vrijednosti širine poželjno u rasponu od 30 mm do 200 mm, te preciznije 40 do 70 mm.
PLASTIC NET BAG, as per claims 1 to 3, characterized by the fact that the width (L2) of the welds (6 and 7) can be variable, provided that it is sufficient so that the whole of the welded mass has a resistance suited to the dimensions and weight of the product packed in the bags, preferentially ranging from 5 mm. to 30 mm., and more specifically from 10 mm. to 15 mm. 
Plastična mrežasta vrećica, prema zahtjevima 1 do 3, naznačena time da širina (L2) zavara (6 i 7) može biti promjenjiva, pod uvjetom da je dovoljna tako da cjelokupna zavarena masa ima dovoljnu čvrstoću koja odgovara dimenzijama i masi proizvoda pakiranog u vrećice, poželjno u rasponu od 5 mm do 30 mm, a točnije od 10 mm do 15 mm.
PLASTIC NET BAG, as per claims 1 to 7, characterized by the fact that the laminar strip (5) forms a handle to hold and carry the bag, since the welds (6 and 7) of this laminar element with the tubular mesh body of the bag are sufficiently resistant. 
Plastična mrežasta vrećica, prema zahtjevima 1 do 7, naznačena time da laminarna traka (5) oblikuje ručke za držanje i nošenje vrećice, budući da zavari (6 i 7) navedenog laminarnog elementa s cjevastim tijelom mreže vrećice imaju dovoljnu čvrstoću.
PLASTIC NET BAG, as per claims 1 to 8, characterized by the fact that the tubular mesh body (2) that forms the body is a thermoplastic that enables welding by fusion to the laminar strip (5), preferentially of the group of polyolefins (polyethylene, polypropylene, ethylenevinylacetate, etc. 
Plastična mrežasta vrećica, prema zahtjevima 1 do 8, naznačena time da je cjevasto mrežasto tijelo (2) koje tvori tijelo vrećice od termoplastičnog materijala koji omogućava fuzijsko zavarivanje laminarne trake (5), a poželjno je iz skupine poliolefina (polietilen, polipropilen, etilenvinilacetat, itd.
), and more preferentially of medium density polyethylene (MDPE); and by the fact that the laminar strip (5) that is welded to the ends or closures of the bag is also a thermoplastic, which enables welding by fusion to the tubular mesh body (2), being preferentially of the group of polyolefins (polyethylene, polypropylene, ethylenevinylacetate, etc. 
), a još poželjnije od polietilena srednje gustoće (MDPE), te time da laminarna traka (5) koja je zavarena na krajeve ili elementi za zatvaranje vrećice su također od termoplastičnog materijala, što omogućuje fuzijsko zavarivanje cjevastog mrežastog tijela (2), te je poželjno iz skupine poliolefina (polietilen, polipropilen, etilenvinilacetat, itd.
PLASTIC NET BAG, as per claim 10, characterized by the fact that the cuts (20) are preferentially provided in the center of the folds that close the closures (3 and 4) of the bag and are oriented perpendicularly to the folded axis thereof. 
Plastična mrežasta vrećica, prema zahtjevu 10, naznačena time da se utori (20) poželjno nalaze se u središtu preklopa koji zatvaraju elemente za zatvaranje (3 i 4) vrećice i usmjereni su okomito na njegovu presavijenu os.
An antithrombotic compound of the formula I oligosaccharide-spacer-GpIIb/IIIa antagonist (I), wherein the oligosaccharide is a negatively charged pentasaccharide residue of Formula B wherein R1 is OCH3 or OSO3, the charge being compensated by positively charged counterions; 
Antitrombotski spoj formule I oligosaharid-razmaknica-antagonist GpIIb/IIIa (I), naznačen time što oligosaharid je negativno nabijeni pentasaharidni ostatak Formule B [image] gdje R1 je OCH3 ili OSO3, a naboj kompenziraju pozitivno nabijeni protuioni;
The compound of claim 5, being in the form of its sodium salt. The compound of claim 5, being 
Spoj u skladu s patentnim zahtjevom 5, naznačen time što je u obliku svoje soli s natrijem.
binds to thymic stromal lymphopoietin or binds to thymic stromal lymphopoietin receptor; and 
veže za limfopoetin strome timusa ili za receptor za limfopoetin strome timusa; i
is selected from the group consisting of an antibody, a peptide or polypeptide. 
bira iz grupe koja se sastoji od antitijela, peptida ili polipeptida.
A gabapentin pharmaceutical composition under the tablet form obtained by compressing a granulate according to claim 1 and known additives useful for the preparation of tablets. 
Farmaceutska smjesa gabapentina, naznačena time što je u obliku tablete dobivene komprimiranjem granulata iz zahtjeva 1 i poznatih aditiva koji su korisni za pripremu tableta.
A gabapentin pharmaceutical composition under tablet form according to claim 7, wherein the additives represent between 0 and 30% by weight and preferably between 0 and 20% by weight of the tablet, the remaining to 100% being a granulate of claim 1. 
Farmaceutska smjesa gabapentina u obliku tablete prema zahtjevu 7, naznačena time što aditivi predstavljaju između 0 i 30% težine tablete i poželjno između 0 i 20% težine tablete, a ostatak do 100% čini granulat iz zahtjeva 1.
A gabapentin pharmaceutical composition under capsule form obtained by filling-in a gelatine capsule with a granulate according to claim 1 and known additives useful for the preparation of pharmaceutical forms in capsule. 
Farmaceutska smjesa gabapentina, naznačena time što je u obliku kapsule dobivene punjenjem želatinske kapsule granulatom iz zahtjeva 1 i poznatim aditivima koji su korisni za pripremu farmaceutskih oblika kapsula.
A gabapentin pharmaceutical composition under capsule form obtained by filling-in a gelatine capsule with a granulate according to claim 12. 
Farmaceutska smjesa gabapentina u obliku kapsule, naznačena time što se kapsula dobiva punjenjem želatinske kapsule granulatom prema zahtjevu 12.
A gabapentin chemical composition under tablet or capsule form containing a granulate according to claim 12. 
Kemijska smjesa gabapentina u obliku tablete ili kapsule, naznačena time što sadrži granulat prema zahtjevu 12.
Preform according to one of the preceding claims, characterised in that said liquid consists of an oil-based liquid. 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što se navedena tekućina sastoji od tekućine na uljnoj bazi.
Preform according to one of the preceding claims, characterised in that said liquid consists of a water containing, respectively water-bound liquid. 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što se navedena tekućina sastoji od tekućine koja sadrži vodu, odnosno tekućinu vezanu vodom.
Preform according to one of the preceding claims, characterised in that at least one additional intermediate layer (4, 5), which is composed of a quaternary material (QM), is provided at at least one contact surface of said secondary layer (2) with respect to the primary, respectively tertiary adjacent layer (1, 3), 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što se barem jedan dodatni međusloj (4, 5), sastavljen od kvartarni materijal (QM), nalazi na barem jednoj dodirnoj površini sekundarnog sloja (2) u odnosu na primarni, odnosno tercijarni susjedni sloj (1, 3),
Preform according to one of the preceding claims, characterised in that said secondary layer (2) consists in a so-called intermediate phase, such as pastes, adhesives, and other substances having a liquid phase under normal conditions of pressure and temperature, which may possibly be converted into a solid phase, in particular by hardening. 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što se sekundarni sloj (2) sastoji od takozvane međufaze, kao što su paste, adhezivi i druge tvari s tekućom fazom pod normalnim uvjetima tlaka i temperature, a koja može prijeći u čvrstu fazu, posebno stvrdnjavanjem.
Preform according to one of the preceding claims, characterised in that at least one of said materials or layers (1, 2, 3, 4, 5) contains a predetermined quantity of additives (71, 73). 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što barem jedan od materijala slojeva (1, 2, 3, 4, 5) sadrži unaprijed određenu količinu aditiva (71, 73).
Preform according to one of claims 8 to 12, characterised in that said additives have a neutralising action on waste or degradation materials originating from the preform itself. 
Predoblik prema jednom od zahtjeva 8 do 12, naznačen time što aditivi djeluju neutralizirajuće na otpadne ili razgradne materijale iz samog predoblika.
Preform according to one of the preceding claims, characterised in that said primary and tertiary materials (PM, TM) are mutually different. 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što su primarni i tercijarni materijali (PM, TM) međusobno različiti.
Preform according to one of the preceding claims, characterised in that said secondary, possibly quaternary materials (SM, QM) are composed of so-called polymer bio-aggregate which are composed by cells and/or cell products which are worked in a polymer. 
Predoblik prema jednom od prethodnih zahtjeva, naznačen time što su sekundarni, i moguće kvartarni materijali (SM, QM) sastavljeni od takozvanog polimera bio-agregata koji je sastavljen od stanica i/ili staničnih proizvoda koji su umreženi u polimer.
the molecules which are bio-chemically synthesised by organisms. 
molekula koje organizmi sintetiziraju biokemijski.
Preform according to one of the claims 15 to 20, characterised in that said organisms are unicellular. 
Predoblik prema jednom od zahtjeva 15 do 20, naznačen time što su organizmi jednostanični.
Container characterised in that it consists of an injection piece obtained from blowing a preform as defined in one of the preceding claims. 
Spremnik naznačen time što se sastoji od uštrcanog komada dobivenog puhanjem predoblika kako je definiran u jednom od prethodnih zahtjeva.
Method for producing a preform in an injection moulding mould according to one of the claims 1 to 22, wherein a predetermined quantity of a primary, respectively tertiary synthetic material (PM, TM) is injected in a hollow mould space under a relatively high pressure p and temperature T, characterised in that a predetermined quantity of a secondary material (SM) is further fed in the hollow mould space under conditions of pressure and/or temperature which are substantially lower than said primary and tertiary injection pressure p, resp. temperature T, wherein said conditions of temperature for the feeding of secondary material (SM) are substantially at room temperature. 
Postupak proizvodnje predoblika, prema jednom od zahtjeva 1 do 22, u kalupu za oblikovanje uštrcavanjem, gdje se unaprijed određena količina primarnog, odnosno tercijarnog sintetskog materijala (PM, TM) uštrcava (injicira) u šuplji prostor kalupa pod relativno visokim tlakom p i temperaturom T, naznačen time što se unaprijed određena količina sekundarnog materijala (SM) dalje unosi šuplji prostor kalupa pod uvjetima tlaka i/ili temperature koji su bitno niži od navedenog tlaka uštrcavanja p, odnosno temperature T za primarni i tercijarni materijal, pri čemu su uvjeti temperature za unos sekundarnog materijala (SM) u biti sobna temperatura.
Method according to the preceding claim, characterised in that said secondary material (SM) is fed under normal conditions of atmospheric pressure and room temperature. 
Postupak prema prethodnom zahtjevu, naznačen time što se sekundarni materijal (SM) unosi pod normalnim uvjetima atmosferskog tlaka i sobne temperature.
Method according to one of claims 24 to 25, characterised in that said secondary material (SM) is fed in a peripheral way on said primary material (PM) during the injection phase thereof and which is conveyed by the latter to said moulding space over a certain distance which is kept relatively small. 
Postupak prema jednom od zahtjeva 24 do 25, naznačen time što se sekundarni materijal (SM) unosi periferno na primarni materijal (PM) za vrijeme faze uštrcavanja i koji je njime prekriven u prostoru kalupa preko određene udaljenosti koja je relativno mala.
Method according to one of the claims 24 to 26, characterised in that predetermined quantity of additives is fed previously to one of said materials with a neutralising action on undesired effects. 
Postupak prema jednom od zahtjeva 24 do 26, naznačen time što se unaprijed određena količina aditiva unosi prije jednog od navedenih materijala s neutralizirajućim djelovanjem na neželjene učinke.